Steven Xu Tan

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Celtic Pharma Management LP is a private equity firm founded by Stephen Evans Freke and John Mayo in 2004. The firm headquartered in Bermuda.

Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California.

Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP.

CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT.

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.

Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon.